Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
IN8bio, Inc. develops gamma-delta (γδ) T cell therapies and γδ T cell engagers for cancer and autoimmune diseases. Company news centers on clinical and preclinical pipeline updates, including DeltEx Drug-Resistant Immunotherapy γδ T cells in newly diagnosed glioblastoma, INB-100 allogeneic γδ T cells for high-risk leukemias after haploidentical stem cell transplantation, and γδ T cell engager work for oncology and autoimmune indications.
Recurring updates also cover financial results, clinical data presentations at medical meetings, R&D communications, financing activity, Nasdaq inducement grants, and leadership or board changes. The company operates as a clinical-stage biopharmaceutical issuer with common stock traded on Nasdaq under INAB.
IN8bio (INAB) presented new preclinical data for INB-619, their gamma-delta T cell engager (TCE) therapy, at the ASGCT 2025 Annual Meeting. INB-619 demonstrated complete elimination of disease-causing B cells in blood samples from Systemic Lupus Erythematosus patients. The therapy successfully targets CD19+ B cells while expanding both Vδ1+ and Vδ2+ gamma-delta T cells.
Key advantages of INB-619 include its ability to deplete harmful IgG1 and IgM antibodies and achieve B cell elimination without triggering severe inflammatory responses like cytokine release syndrome (CRS). Unlike traditional CD3-based TCEs, the platform shows potential for safer and more precise immunotherapy for autoimmune diseases.
The company is exploring partnerships and additional indications where gamma-delta T cell biology and B cell targeting intersect.IN8bio (NASDAQ: INAB) presented new data on its proprietary gamma-delta (γδ) T cell manufacturing program at ISCT 2025, receiving the Host Region Abstract Award. The company's DeltEx™ Allo manufacturing process demonstrated consistent production of potent cellular therapies for cancer treatment.
Key findings from the INB-100 study revealed: (1) Successful TCR reprogramming from αβ to γδ across all clinical batches, (2) High expression of cancer-killing and immune activation genes, and (3) Remarkable clinical outcomes with all 10 initial cohort patients remaining relapse-free for over a year, achieving a median overall survival of 23.3 months as of January 2024.
The company has automated its manufacturing program for rapid, reproducible production of cryopreserved cell therapy doses. The INB-100 trial is currently enrolling an expansion cohort at the recommended Phase 2 dose.
IN8bio (Nasdaq: INAB) announced upcoming presentations of new clinical and preclinical data from its gamma-delta T cell therapies platform at major scientific conferences. The company will showcase its research at four prestigious events: AACR 2025, ISCT 2025, ASGCT 2025, and ASCO 2025.
Key presentations include:
- A novel gamma-delta T cell engager platform for cancer immunotherapy at AACR
- Manufacturing processes and TCR repertoire analysis at ISCT
- INB-600 T cell engager platform and molecular signatures at ASGCT
- Phase 1 study results of INB-200 in glioblastoma patients at ASCO
CEO William Ho emphasized the scientific rigor and clinical potential of their platform, highlighting applications in both oncology and immune-mediated diseases. The presentations will focus on their INB-200/400 program in glioblastoma and novel T cell engager technologies.
IN8bio (NASDAQ: INAB) has unveiled promising preclinical data from its gamma-delta (γδ) T cell engager (TCE) platform at AACR 2025. The company's novel platform demonstrates significant γδ T cell expansion and activation without serious side effects like cytokine release syndrome.
The platform's lead molecules, INB-619 (targeting CD19) and INB-633 (targeting CD33), showed potent anti-cancer activity in leukemia models at low picomolar concentrations. Unlike traditional TCEs that activate all T cells through CD3, IN8bio's platform specifically activates γδ T cells, potentially offering a safer alternative with minimal inflammatory cytokine release.
Key findings show both molecules successfully expanded Vδ1+ and Vδ2+ cell subsets and demonstrated strong cancer-killing capabilities without triggering dangerous cytokine responses. The platform's off-the-shelf nature, requiring no genetic engineering, suggests potential for scalable immunotherapy development for both cancer and autoimmune diseases.
IN8bio (NASDAQ: INAB) has announced it will present new preclinical data on its novel gamma-delta (γδ) T cell engager platform at the AACR Annual Meeting 2025 in Chicago. The presentation will showcase the company's innovative approach to cancer immunotherapy, combining gamma-delta T cells' innate tumor-recognition capabilities with bispecific engagers.
The research focuses on overcoming limitations of current CD-3 based engager therapies by leveraging unique properties of gamma-delta T cells, including tissue residence, phagocytosis, and low IL-6 secretion. Early findings in AML and B-ALL demonstrate potential for targeted immune responses against multiple antigens.
The poster presentation titled 'A novel gamma-delta T cell engager platform for cancer immunotherapy' (Abstract #7321) will be presented on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, has announced its participation in the 11th Annual Immuno-Oncology 360° Conference 2025 in Boston, MA from March 24-26, 2025.
William Ho, CEO and co-founder, will serve as Co-Chair for Day 2 on March 25, leading key sessions including:
- Welcome remarks and discussion on 'Tackling the Tough Questions in IO for Autoimmunity Disease' at 8:15 AM EDT
- Chairing the 'State of the IO Market, Investments and Deals Plenary'
- Presentation on 'Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager' at 4:35 PM EDT
The presentations will highlight IN8bio's recently announced INB-619 T cell engager program for oncology and autoimmune diseases, focusing on the potential of gamma-delta T cell engagers in addressing autoimmunity.
IN8bio (INAB) reported its Q4 and full-year 2024 financial results, highlighting significant clinical progress in its gamma-delta T cell therapies. The company's INB-100 program demonstrated 100% long-term durable response rates in high-risk AML patients as of January 2025. The Phase 1 INB-200 trial for glioblastoma showed promising durability, with five patients remaining alive and one patient progression-free for 40.5 months.
Financial highlights include R&D expenses of $17.2M for 2024 (vs $16.8M in 2023), G&A expenses of $12.6M (vs $13.5M), and a net loss of $30.7M ($0.57 per share). The company ended 2024 with cash of $11.1M, raised additional $4.1M in February 2025, and expects runway into March 2026.
IN8bio introduced its INB-600 platform featuring a novel gamma-delta T Cell engager targeting CD19 for oncology and autoimmune diseases. The company implemented cost-saving measures and paused the Phase 2 INB-400 glioblastoma program to optimize resource allocation.
IN8bio (NASDAQ: INAB) has unveiled INB-600, a novel gamma-delta (γδ) T cell-based TCE platform designed to overcome the limitations of current γδ TCEs. The platform's first candidate, INB-619, targets CD19 for applications in leukemias, lymphomas, and autoimmune diseases.
Key preclinical findings for INB-619 include:
- Rapid B-cell depletion with γδ T cells expanding up to 450-fold
- Simultaneous activation of both Vδ1+ and Vδ2+ T cell subsets
- Lower IL-6 secretion, potentially reducing risks of cytokine release syndrome (CRS) and neurotoxicity (ICANs)
The platform represents the first known approach capable of sustained γδ T cell expansion, offering potentially greater safety and tolerability compared to current CAR-T and TCE approaches. IN8bio plans to evaluate INB-619 in preclinical studies and seek partners for future IND-enabling trials.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. William Ho, CEO and co-founder, will deliver a presentation on Monday, March 3, 2025, at 10:30 a.m. ET.
Interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section within the News & Presentations area on IN8bio's investor relations website at https://investors.in8bio.com.